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Abstract: Newborn screening (NBS) for cystic fibrosis (CF) has been shown to be advantageous
for children with CF, and has thus been included in most NBS programs using various algorithms.
With this study, we intend to establish the most appropriate algorithm for CF-NBS in the Portuguese
population, to determine the incidence, and to contribute to elucidating the genetic epidemiology of
CF in Portugal. This was a nationwide three-year pilot study including 255,000 newborns (NB) that
were also screened for congenital hypothyroidism (CH) and 24 other metabolic disorders included in
the Portuguese screening program. Most samples were collected in local health centers spread all
over the country, between the 3rd and 6th days of life. The algorithm tested includes immunoreactive
trypsinogen (IRT) determination, pancreatitis associated protein (PAP) as a second tier, and genetic
study for cases referred to specialized clinical centers. Thirty-four CF cases were confirmed positive,
thus indicating an incidence of 1:7500 NB. The p.F508del mutation was found in 79% of the alleles.
According to the results presented here, CF-NBS is recommended to be included in the Portuguese
NBS panel with a small adjustment regarding the PAP cut-off, which we expect to contribute to the
improvement of the CF-NBS performance. According to our results, this algorithm is a valuable
alternative for CF-NBS in populations with stringent rules for genetic studies.
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1. Introduction
Cystic fibrosis (CF, OMIM 219700) is a monogenic, autosomal recessive, inherited, multi-systemic
disease common in the Caucasian population [1,2]. It results from mutations in the CFTR
(CFTR; MIM#602421) gene encoding the CF transmembrane conductance regulator (CFTR) protein,
a chloride (Cl−)/bicarbonate channel functioning at the apical surface of epithelial cells [3,4].
The absence or dysfunction of the CFTR protein affects exocrine secretion, leading to a positive sweat
Cl− test (SCT) (a Cl− concentration in sweat ≥ 60 mEq/L). Pulmonary, pancreatic and hepatobiliary
symptoms, as well as male infertility, are typical signs of CF. Despite large clinical heterogeneity,
respiratory tract symptoms dominate CF pathology, with early impaired pulmonary function and
lung disease being the major cause of morbidity and mortality in CF [5]. Adding to the broad
phenotypic spectrum, a large genotypic variety is also observed (particularly in some regions, like
Southern Europe), with genotype–phenotype correlations difficult to establish due to the involvement
of multiple genetic modifiers and environmental factors [6,7].
More than 2000 CFTR coding gene sequence variations have been reported (CFTR Mutation
Database), but only a small percentage of these have a demonstrated CF-causative effect
(www.cftr2.org, accessed on 6 April 2018) [8,9]. Despite such high genetic heterogeneity, there is
one single mutation (p.F508del), which is present in 70% of CF patients worldwide, thus being the
most common CF-causing mutation [10,11]. Important clinical trials are ongoing for new drugs
specifically designed to improve CFTR expression and function on a mutation-specific basis, and these
will likely contribute to significantly increasing the life expectancy of patients and their quality of
life [6,12,13].
CF has been included in most newborn screening (NBS) programs based on well-recognized,
long-term benefits [14–17]. Starting in New Zealand and Australia, it is now included in all states
of the USA and most European countries [18]. Ultimately, all NBS programs refer infants with a
positive screening test to a specialized CF center for SCT and clinical evaluation so as to confirm a
diagnosis of CF. It is necessary to obtain evidence of CFTR dysfunction through the identification of two
CFTR gene mutations previously assigned as CF-causing, two tests showing a high Cl− concentration
in sweat (>60 mEq/L), distinctive transepithelial nasal potential difference (NPD) measurements,
and/or assessment of CFTR (dys)function in native colonic epithelia ex vivo [19–22]. Accordingly,
such programs have high variability in terms of organization and algorithms. Indeed, NBS algorithms
differ by country (also often by regions within the same country), but they usually start with IRT
determination, with positive results triggering second-tier tests which can be either DNA analysis or
PAP determination. Some algorithms also include the request of a second sample for IRT determination,
and each algorithm has its own sensitivity and specificity [17]. Each program adopts an algorithm
which is adapted to the characteristics of the population being tested, and matches the health system
conditions of each country [6].
Here, we describe results from a three-year pilot study for CF-NBS conducted in Portugal and
including 255,000 NB, with the aim of establishing the most appropriate conditions that identify the
majority, if not all, of Portuguese individuals with CF and selecting the most suitable algorithm for the
implementation of CF-NBS in our country, taking into account its specific features.
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2. Materials and Methods
2.1. Population in the Study
This study was submitted to the ethical committee for health from the National Institute of Health
Doutor Ricardo Jorge (approval date: 28 October 2013, approval number CD2013/121304554).
This pilot study for CF-NBS started at the end of 2013 and included a total of 255,000 NB.
Posters and leaflets containing information regarding CF and the importance of CF screening were
provided to the sampling centers, together with the sampling cards. Information regarding this
study was also available at the Portuguese NBS website (www.diagnosticoprecoce.pt, accessed on
6 April 2018) and meetings about NBS are promoted for health care professionals enrolled in NBS every
six months. Samples for CF screening are the same used for metabolic and CH screenings, and are
mainly collected in local health centers spread all over the country between the 3rd and 6th days of
life [23]. CF-NBS is carried out on a voluntary basis, with parents deciding at the time of NBS sample
collection whether they want CF screening to be included in their baby’s NBS. If the parents decide to
opt-out from the CF pilot study, this is indicated on the screening card. During the three years of the
present study, only four couples opted out CF-NBS.
2.2. CF-NBS Algorithm
In this study, an IRT/PAP/IRT algorithm was used, as shown in Figure 1. IRT quantification
was performed by a sandwich time-resolved immunofluorometric assay, using the AutoDELFIA®
system from PerkinElmer (Waltham, MA, USA). Samples with IRT values above 65 ng/mL after
repeated measurement on the same sample were selected for PAP determination. PAP quantification
was also done by a sandwich time-resolved imunofluorometric assay, using the MucoPAP-F kit from
Dynabio (Lyon, France). A double PAP cut-off, depending on IRT value, was used according to the
manufacturer’s indication. An ultrahigh IRT cut-off (150 ng/mL) was also used for direct request of a
second sample (as a “safety net” [24]), independently of PAP value.
Second dried blood spots (DBS) were typically collected in the 3rd week of life, and children
presenting with IRT ≥ 50 ng/mL were referred to specialized CF clinical centers for clinical evaluation
and SCT, usually at around one month of age.
Pancreatic status was determined based on the fecal elastase (FE) value and considered as
pancreatic insufficient (PI) if FE < 200 µg/g, or pancreatic sufficient (PS) if higher. SCT was performed
according to a standardized protocol. If the result was clearly negative (<30 mEq/L), the case was
considered to be a false positive. If the result was positive (≥60 mEq/L) or borderline (≥30 and
<60 mEq/L), a written informed consent for CFTR gene study was requested from the parents by the
clinician and sent to the NBS laboratory. Genetic studies were immediately started using genomic DNA
extracted from the remaining DBS blood. In a first level approach, the p.F508del mutation is tested by
Amplification-Refractory Mutation System (ARMS) analysis (method adapted from Ferrie et al. [25]).
If the result is not homozygosity for p.F508del mutation, genetic study proceeds using Elucigene®
CF-EU2v1 kit (screening for 50 Europe-frequent mutations, Elucigene Diagnostics, Manchester, UK)
and Elucigene® CF Iberian Panel kit (screening for 12 Iberian Peninsula-frequent mutations). In the
cases of positive SCT and only one or no CF mutations identified, the complete sequencing of the
CFTR gene by next-generation sequencing (NGS) is suggested.
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3. Results
In this study, 255,000 NB were screened. 1785 (0.7%) were identified with an increased IRT value
in the screening sample (≥65 ng/mL), but only 1020 (0.4%) met the criteria for a second sample request
(Figure 1). From these, 990 samples were received (97%), mainly collected between the 3rd and 4th
weeks of life. In most cases for which a second sample was not received, the newborns were very
sick and premature, and were deceased. A total of 78 cases (7.9% of second samples) had persistent
increased IRT results and were thus referred to a CF specialized treatment center. From these cases,
32 (41%) could be confirmed as CF. Twenty-nine cases were confirmed as being CF-positive based on a
positive SCT result (Table 1).
Table 1. CF patients identified in the CF-NBS pilot study.
Sampling Day Birth Weight(g)
Newborn Screening Results
Sweat Test
(nmol/L)
Fecal Elastase
(µg/g)
CFTR Gene
1st IRT
(ng/mL)
PAP
(ng/mL)
2nd IRT
(ng/mL) Allele 1 Allele 2
P1
(5, 15) 3040 94 5.4 158 116 1 p.F508del p.F508del
P2
(21, –) 3375 130 3.9 n.d. 112 <30 p.F508del p.F508del
P3
(6, 17) 2700 210 >8.8 287 110 <15 p.F508del ?
P4
(23, 28) 3170 190 >8.8 195 109 1 p.F508del p.F508del
P5
(3, 13) 2555 260 4.3 344 128 <15 p.F508del p.F508del
P6
(4, 27) 2300 266 >8.8 360 115 n.a. p.F508del p.F508del
P7
(5, 15) 2695 443 >8.8 531 120 <15 p.F508del p.F508del
P8
(2, 5) 2710 101 >8.8 101 121 <30 p.F508del p.F508del
P9
(4, 30) 2870 110 4.6 123 108 <15 p.F508del p.F508del
P10
(3, 16) 3825 414 >8.8 265 84 <15 p.F508del p.F508del
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Sampling Day Birth Weight(g)
Newborn Screening Results
Sweat Test
(nmol/L)
Fecal Elastase
(µg/g)
CFTR Gene
1st IRT
(ng/mL)
PAP
(ng/mL)
2nd IRT
(ng/mL) Allele 1 Allele 2
P11
(5, 19) 3855 238 5.2 281 93 107 p.F508del p.R792X
P12
(4, 21) 3750 241 7.8 333 110 <15 p.F508del p.F508del
P13
(5, 21) 2860 305 5.1 135 87 28 p.F508del p.F508del
P14
(5, 18) 3380 156 4.7 219 95 <30 p.F508del Ex 3 total deletion
P15
(6, 23) 3850 133 7.6 157 78 <5 p.F508del p.F508del
P16
(3, –) 3438 91 >8.8 n.d. 90 <30 p.F508del p.F508del
P17
(5, 27) 3320 113 5.8 133 104 <15 p.F508del p.F508del
P18
(5, 12) 2860 463 >8.8 624 76 <5 p.F508del p.F508del
P19
(4, 14) 1950 215 >8.8 155 100 20 p.G85E p.R1066C
P20
(4, 12) n.a. 255 >8.8 282 89 <10 p.F508del p.F508del
P21
(3, 17) 3120 259 >8.8 185 n.a. n.a. p.N1303K p.R1066C
P22
(3, 20) 3325 70 2.3 55 70 312 p.F508del p.V232D
P23
(4, 23) 2560 107 7.3 191 78 25 p.F508del p.F508del
P24
(3, 17) 2500 258 5.6 269 n.a. <15 p.F508del p.F508del
P25
(5, 18) 2950 240 9.3 244 88 13 p.F508del p.F508del
P265, 18) 3265 113 ≥8.8 136 83 <15 p.F508del p.F508del
P27
(3, 15) 2760 160 9.0 172 122 72 p.F508del p.N1303K
P28
(13, 28) 2235 67 ≥8.8 51 n.a. <5 p.F508del p.F508del
P29
(5, 21) 3640 75 1.6 123 134 <15 p.F508del p.R1162X
P30
(4, 15) 3100 397 ≥8.8 306 69 40 p.F508del p.G85E
P31
(3, 28) 3070 103 ≥8.8 83 88 <30 p.F508del p.F508del
P32
(4, –) 2860 202 2.7 n.d. n.a. n.a. p.F508del p.N1303K
P33
(10, 28) 3840 54 7.5 49 n.a. <10 p.F508del p.F508del
P34
(5, 49) 3555 108 ≥8.8 11 110 <100 p.G542X p.G542X
Legend: Patients 5 and 6 are twin brothers; P6 deceased due to cardiomyopathy; SCT was not performed for
patients 28 and 33 due to the absence of adequate clinical conditions (both patients presented with meconium ileus).
n.a.—not available.
Furthermore, three additional NB were confirmed positive for CF but not based on NBS (Table 1,
patients 32–34). Patient 32 was born on Madeira Island, right after the beginning of this study and
was not initially included in CF screening. At the age of six months, due to CF clinical suspicion,
its screening sample was retrospectively analyzed for IRT and PAP, revealing a positive result for
CF-NBS. Patient 33 was a NB who already had a positive prenatal diagnosis of CF, and who also
presented with meconium ileus. In the case of Patient 34, a second sample was requested due to
increased IRT and PAP, but this child was already at the hospital due to biliary atresia. Therefore,
a second sample was only collected on the 49th day of life, and after several blood transfusions,
which may explain the low IRT value in the second sample. Characterization of all CF-positive cases is
presented in Table 1. Mutation p.F508del was present in 54/68 (79%) of the alleles; only three patients
did not present with this mutation and in one case, the second mutation could not be identified
(although all the CFTR exonic and flanking intronic regions had been sequenced). Complete CFTR
gene sequencing is still in progress.
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Considering the 34 cases confirmed as CF positive, a 1:7500 incidence was found for CF. This pilot
study allowed the identification of an additional patient, the 7-year-old brother of Patient 1, who
had a previous diagnosis of asthma. Follow-up was also recommended for a brother of an older
CF-patient with a negative CF prenatal diagnosis. They presented with an elevated IRT value at
screening, leading to the request of a second sample and referral to a CF center (first sample (day 6):
IRT-79 ng/mL, PAP-2.0 ng/mL; second sample (day 17): IRT-65 ng/mL). Genetic study revealed a
p.R334W/5T genotype, thus excluding a CF diagnosis.
From the 78 cases referred to a CF specialized treatment centre for further evaluation, 46 (59%)
could not be confirmed as CF-positive (0.018% of the total screened). Of these cases, five were found to
be heterozygous for CF mutations detected in the screening-included genetic study. According to the
information received from CF specialized treatment centers, one positive case was missed (Patient 34).
Patient 33, who had meconium ileus and a positive pre-natal diagnosis, could have been identified
due to increased PAP.
During approximately four months, 30,000 NB were screened using a lower first IRT cut-off
(50 ng/mL). This alteration in the algorithm led to 400 more PAP determinations and 20 additional
requests of second samples. All cases presented normal IRT values in the second sample, and thus this
cut-off was no longer used.
4. Discussion
Between 1992–1995, a pilot study for CF-NBS had already been performed for NB in the North and
Center of Portugal. It included the screening of 40,000 NB, but only four CF patients were identified,
corresponding to a birth prevalence of 1:10,000 NB. Due to this low value, the high number of false
positive results (>1%), and to the low efficacy of the treatment available at that time, it was decided
not to proceed with this screening.
In 2013, we started a second pilot CF-NBS program as a one-year collaboration project with the
Portuguese National Association for Tuberculosis and Respiratory Diseases. At the end of the project,
the National Technical Committee for NBS decided that the results supported the maintenance of the
pilot study, with the possibility of opting out. To date, 255,000 NB have been screened for CF and
during these three years, only four couples refused the participation of their children in the pilot study.
When restarting the CF-NBS pilot study in 2013, it was necessary to redefine the algorithm and
cut-off values to be used to increase its positive predictive value (PPV). Several protocols with different
sensitivities and specificities were reported in the literature, and to decide which one to use in Portugal,
two main aspects were considered: (1) National Program’s organization, including sampling collection
day, and (2) legal issues for genetic studies in our country.
The Portuguese NBS program works with no written informed consent or dissent, and although
not mandatory, it has an excellent coverage rate (close to 100%). Because genetic studies cannot be
done with a presumptive informed consent in Portugal, we decided not to include genetic study in the
first level CF-NBS protocol. Two other factors contributed to this decision: the genetic heterogeneity
predicted for the Portuguese population and the intention of minimizing the identification of healthy
CF carriers and cases of CF-screening positive with an inconclusive diagnosis (CFSPID). Once the DNA
tier had been excluded, we decided on an algorithm including PAP [26] because we wanted to decrease
the recall rate. Compared to an IRT/IRT protocol which we had previously tested in the first pilot study
in 1992, no good results were obtained due to the large number of false positive results, which affected
parents’ anxiety due to prolonged uncertainty about a CF diagnosis. Although IRT quantification is
widely accepted as a first marker, it is known that it is not 100% sensitive [27], and the establishment
of an adequate cut-off value is a critical step in the optimization of a CF NBS program. A 65 ng/mL
fixed cut-off was chosen based on the 99th percentile value calculated for 20,000 samples. Regarding
the PAP cut-off value, reports available in the literature were mainly supportive of photometric
determination and there wasn’t a consensual PAP cut-off value [28–30]. Dynabio recommendations for
the fluorometric determination were adopted here. The use of PAP in our algorithm reduced the initial
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abnormal results from 0.7% to 0.4% (i.e., by 43%), yet a high number of cases would be considered
positive. To overcome this problem, a second sample for IRT determination was requested from these
cases. This procedure drastically reduced the number of false positive cases referred to clinical centers
for evaluation (by 92%). Only 78 cases had IRT levels that remained elevated in the second sample
(of which 46 could not thus far be confirmed CF-positive), representing a 0.018% rate of possible false
positive cases referred to CF clinical centers. Performance indicators achieved for the IRT/PAP/IRT
algorithm are indicated in Table 2.
Table 2. Performance indicators for IRT/PAP/IRT algorithm.
Screened newborns (n) 255,000
Confirmed CF patients (n) 34
False positives referred for SCT (n) 46
False negatives, including cases with meconium ileus (n) 2
Sensitivity, % [IC 95%] 94.44% [81.85–98.47%]
Specificity, % [IC 95%] 99.98% [99.98–99.99%]
PPV, % [IC 95%] 41.03% [30.78–52.11%]
PAP cut-offs adopted in this study were revealed to be too low, still resulting in a high recall rate.
To make PAP a valid tier in this algorithm, PAP cut-offs should be changed. The IRT-dependent PAP
cut-off also does not seem to present any advantage. No CF patient was identified with a PAP value
lower than 1.6 ng/mL, and using this value as a single PAP cut-off, 161 requests of a second sample
could be avoided (six of which were false positive cases referred to CF clinical centers).
The use of a safety net also contributed to the significant number of second sample requests, and all
patients would have been identified without it. Based on these observations, the algorithm currently in
use does not include the safety net and uses a unique 1.6 ng/mL cut-off for PAP. These changes should
be revised in a period of 2–3 years, depending on the results obtained or reported by other countries.
PAP may also be a valuable tool to identify NB with meconium ileus due to CF, which are known to
potentially have normal IRT values. All patients in this study presenting with this condition were found
to have elevated PAP results, even in the presence of normal IRT results, which is the case in Patient 33.
PAP determination is done in all cases referred due to meconium ileus, even in the presence of a normal
IRT value. Identifying a large number of cases will be necessary to draw final conclusions. Any case
with a suspicion of CF reported to the NBS laboratory (including NB with respiratory symptoms or
meconium ileus, but with first IRT under 65 ng/mL cut-off), was retrospectively subjected to IRT
re-determination, PAP determination and genetic study if written informed consent was obtained from
the parents. More than 20 of these cases have been analyzed, but none were confirmed as CF positive.
Currently, PAP is also determined in the second sample. It is known that it changes significantly
during the postnatal period (increasing with age), but it seems to increase much more rapidly in CF
patients according to some authors [31]. Although our data are too preliminary to draw a definitive
conclusion, PAP values in the second sample may also be important to discriminate true positives
from false positive cases.
Genetic confirmation can be a prompt and definitive way to confirm CF diagnosis, especially in
cases with inconclusive SCT results. Therefore, a basic genetic study was included in the NBS protocol
after written informed consent was requested by CF center clinicians from the parents. Early molecular
characterization of individuals with a CF diagnosis can be vital for improved CF-specific care,
with personalized treatment (mutation-targeted CFTR modulator therapy), clarification of atypical
cases, and genetic counselling of risk couples regarding recurrence possibilities and prenatal diagnosis.
Using this strategy, we genetically confirmed the diagnosis of 29 out of 32 screening-identified patients.
Five carriers of one CFTR mutation, who could not be confirmed as CF-patients, were also found.
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Regarding the genetic characterization of the CF patients, the p.F508del mutation was found
to have a frequency of 79%, which is higher than expected from existing data which indicated
frequencies between 52% and 63% [32–34]. One possibility for this is that the former values included
adult non-classic CF patients that may escape NBS identification, and among which p.F508del
mutations have a lower frequency. Furthermore, some severe cases (among which p.F508del has
a high frequency) may not have been accounted for in the past, because they could have died before
diagnosis. The first possibility is more plausible since other mutations previously reported to occur in
Portuguese individuals with CF were also not represented in the current population of positive CF
cases. These mutations (frequencies as in the WHO report [33]) include: A561E (3.2%); R334W (2.8%);
G576A (1.4%); 711 + 1G > T and 3272–26A > G (1.0% each); Y1092X (0.8%); R74W, 621 + 1G > T,
Q1100P and I1234V (0.6% each). In fact, the other non-p.F508del mutations which were identified in
the current cohort of NBS positives also corresponded to frequencies slightly higher than previously
described (frequencies as in the WHO Report [33]), namely: 2.9% for R1066C (2.8% before), 2.9% for
G542X (2.6% before), 2.9% for G85E (2.2% before) and 4.4% for N1303K (1.8% before). Strikingly,
none of the mutations detected in the current CF-NBS cohort are associated with PS, although they
exist in significant frequency in Portuguese CF patients (e.g., 3272–26A > G, R334W).
CF incidence calculated from the present CF-NBS results (1:7500 NB) is lower than expected
from registered patients in Portuguese CF specialized clinical centers. Similar results were found in
other countries at the time of NBS implementation [17,35], which may indicate that previous estimates
were not very accurate. It is also possible that some milder cases, namely PS with no early clinical
manifestations, are not being identified. According to the Wilson-Jungner criteria [36], the identification
of these milder late-revealing cases should not be the aim of NBS; nevertheless, their identification
would be advantageous by allowing earlier action. Further investigation is needed to evaluate this
hypothesis. Along these lines, we are already aware of one missed case due to blood transfusion before
sampling. This case was meanwhile identified, but we know that before NBS, a significant number
of CF diagnoses were done after the age of 3 years [37], so we will have to wait some more years to
confirm our results and thus validate the above data.
5. Conclusions
According to the results presented here, CF-NBS is being included in the Portuguese NBS panel
with some adjustments in the algorithm: A unique PAP cut-off will be used (1.6 ng/mL) and no safety
net for ultra-high IRT will be used. With the new algorithm, we expect to improve the performance of
CF-NBS screening, achieving better specificity while maintaining the sensitivity.
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Abbreviations
ARMS Amplification-Refractory Mutation System
CF Cystic Fibrosis
CFTR Cystic fibrosis transmembrane conductance regulator
CFSPID Cystic fibrosis screen positive with an inconclusive diagnosis
DBS dry blood spots
FE fecal elastase
IRT Immunoreactive trypsinogen
NB newborn
NBS Newborn screening
PAP Pancreatitis associated protein
PI pancreatic insufficient
PS pancreatic sufficient
SCT Sweat chloride (Cl−) test
PPV Positive predictive value
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